← Back to Search

Mindfulness Program

Tailored Mindfulness Program for Fear of Memory Loss for Anxiety and Fear

N/A

Waitlist Available

Research Sponsored by Northwestern University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 10 week post-baseline

Awards & highlights

Study Summary

This trial will compare the effects of two different programs to help manage anxiety in older adults with dementia.

Eligible Conditions

Anxiety and Fear

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 10 week post-baseline

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~10 week post-baseline

This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 week post-baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change of Fear and Avoidance of Memory Loss (FAM) Scale score at follow-up

Change of Fear of Alzheimer's Disease Scale (FADS) score at follow-up

Secondary outcome measures

Coronavirus Anxiety Scale (CAS)

Memory Failure Scale (MFS)

Patient Global Impression of Change (PGIC)

+2 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Tailored Mindfulness Program for Fear of Memory LossExperimental Treatment1 Intervention

Tailored mindfulness lessons and activities for fear of memory loss.

Group II: Conventional Mindfulness ProgramActive Control1 Intervention

Routine mindfulness lessons and activities.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Tailored Mindfulness Program for Fear of Memory Loss

2021

N/A

~90

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor

1,585 Previous Clinical Trials

917,150 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What conclusions is this clinical research attempting to prove?

"The primary outcome of this medical trial, assessed over a 10-week period post-baseline is the Change in Fear of Alzheimer's disease Scale (FADS) score at follow up. Secondary outcomes include the Patient Global Impression of Change (PGIC), Patient Reported Outcome Measures Information System-29 (PROMIS-29), and Coronavirus Anxiety Scale (CAS)."

Answered by AI

Is there currently an open enrollment period for this research?

"According to the details posted on clinicaltrials.gov, this medical trial is still searching for participants with a first post date of May 17th 2021 and last update occurring August 2nd 2022."

Answered by AI

How many participants are receiving care in this experiment?

"Affirmative. Clinicaltrials.gov reflects that this clinical trial, which was first made available on May 17th 2021, is currently recruiting patients. Approximately 80 participants must be enrolled from a single location."

Answered by AI